{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T18:38:51Z","timestamp":1777747131502,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ContraFec"},{"name":"Spanish Network for Research in Infectious Diseases"},{"name":"REIPI","award":["RD06\/0008"],"award-info":[{"award-number":["RD06\/0008"]}]},{"name":"Sara Borrell personal research","award":["CD21\/00125, 2022-24"],"award-info":[{"award-number":["CD21\/00125, 2022-24"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pla estrat\u00e8gic de recerca i innovaci\u00f3 en salut"},{"name":"Juan Rod\u00e9s Research","award":["J23\/00035, 2024-28"],"award-info":[{"award-number":["J23\/00035, 2024-28"]}]},{"name":"Ministerio de Economia y Competitividad, Madrid"},{"DOI":"10.13039\/100030957","name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Infective endocarditis (IE) is a severe infection mainly caused by Staphylococcus aureus, Enterococcus faecalis and viridans streptococci. Coagulase-negative staphylococci (CoNS), especially methicillin-resistant Staphylococcus epidermidis (MRSE), are major pathogens in prosthetic valves and devices. Exebacase is a first-in-class, antistaphylococcal lysin with rapid bactericidal and antibiofilm activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the in vitro activity of exebacase and standard IE antibiotics against S. aureus and CoNS isolates from IE patients in a university hospital (2010\u20132020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 211 consecutive strains were analysed: S. aureus [n\u200a=\u200a103 (82 MSSA, 21 MRSA)], S. epidermidis [n\u200a=\u200a76 (20 MSSE, 56 MRSE)] and other CoNS species (n\u200a=\u200a32, Staphylococcus haemolyticus, Staphylococcus lugdunensis, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus schleiferi, Staphylococcus caprae, Staphylococcus pasteuri). Broth microdilution MICs were determined for exebacase and comparators (cloxacillin, ceftaroline, vancomycin, daptomycin, gentamicin, rifampicin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Exebacase inhibited all S. aureus at \u22641\u2005mg\/L. Geometric mean (GM) MICs were 0.56\u2005mg\/L for MSSA and 0.49\u2005mg\/L for MRSA, with MIC50\/90 of 0.5\/1\u2005mg\/L. For S. epidermidis, GM MICs were 3.03\u2005mg\/L (MSSE) and 3.40\u2005mg\/L (MRSE), with MIC50\/90 of 4\/16 and 4\/8\u2005mg\/L, respectively. Other CoNS showed GM MICs ranging from 0.49\u2005mg\/L (S. capitis) to 2.59\u2005mg\/L (S. lugdunensis), with intermediate values for S. haemolyticus (1.15), S. hominis (1.0) and S. schleiferi (0.79). Exebacase activity was comparable to \u03b2-lactams, vancomycin and daptomycin and remained unaffected by resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Exebacase activity was independent of methicillin resistance and consistently higher against S. aureus than S. epidermidis. Further research is warranted to explore lysins in combination against staphylococcal infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf435","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:01:23Z","timestamp":1762520483000},"source":"Crossref","is-referenced-by-count":1,"title":["<i>In vitro<\/i>\n                    exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant\n                    <i>Staphylococcus aureus<\/i>\n                    and coagulase-negative staphylococci strains isolated from patients with infective endocarditis"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0521-7204","authenticated-orcid":false,"given":"Mar\u00eda-Alexandra","family":"Ca\u00f1as","sequence":"first","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7075-943X","authenticated-orcid":false,"given":"Guillermo","family":"Cuervo","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER Thematic Area of Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Krivak","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Hern\u00e1ndez-Meneses","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carles","family":"Falces","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Perissinotti","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Vidal","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Tolosana","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Quintana","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Llopis","sequence":"additional","affiliation":[{"name":"Microbiology, Genetics and Statistics Department, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Schuch","sequence":"additional","affiliation":[{"name":"ContraFect Corporation , Yonkers, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0585-9469","authenticated-orcid":false,"given":"Cristina","family":"Garc\u00eda-De-La-M\u00e0ria","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-7755","authenticated-orcid":false,"given":"Jos\u00e9 M","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"Hospital Clinic\u2014Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER Thematic Area of Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Reial Academia de Medicina de Catalunya , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2026011413271736800_dkaf435-B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/cdt.2016.08.09","article-title":"Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study","volume":"7","author":"Cresti","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026011413271736800_dkaf435-B2","doi-asserted-by":"publisher","first-page":"101397","DOI":"10.1016\/j.cpcardiol.2022.101397","article-title":"Demographic and regional trends of infective endocarditis-related mortality in the United States, 1999 to 2019","volume":"48","author":"Agha","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2026011413271736800_dkaf435-B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11886-018-1043-2","article-title":"Infective endocarditis: update on epidemiology, outcomes, and management","volume":"20","author":"Vincent","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"2026011413271736800_dkaf435-B4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jacc.2024.09.027","article-title":"A contemporary picture of coagulase-negative staphylococcal endocarditis: a nationwide GAMES cohort study","volume":"85","author":"Palom-Grau","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026011413271736800_dkaf435-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-41888-7","article-title":"Risk of endocarditis among patients with coagulase-negative Staphylococcus bacteremia","volume":"13","author":"Ramos-Mart\u00ednez","year":"2023","journal-title":"Sci Rep"},{"key":"2026011413271736800_dkaf435-B6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nrmicro2182","article-title":"Staphylococcus epidermidis\u2014the \u201caccidental\u201d pathogen","volume":"7","author":"Michael","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"2026011413271736800_dkaf435-B7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejcb.2009.10.005","article-title":"Structure, function and contribution of polysaccharide intercellular adhesin (PIA) to Staphylococcus epidermidis biofilm formation and pathogenesis of biomaterial-associated infections","volume":"89","author":"Rohde","year":"2010","journal-title":"Eur J Cell Biol"},{"key":"2026011413271736800_dkaf435-B8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41564-018-0230-7","article-title":"Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis","volume":"3","author":"Lee","year":"2018","journal-title":"Nat Microbiol"},{"key":"2026011413271736800_dkaf435-B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02291-18","article-title":"The antistaphylococcal lysin, CF-301, activates key host factors in human blood to potentiate methicillin-resistant Staphylococcus aureus bacteriolysis","volume":"63","author":"Indiani","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/v10060310","article-title":"Development of phage lysins as novel therapeutics: a historical perspective","volume":"10","author":"Fischetti","year":"2018","journal-title":"Viruses"},{"key":"2026011413271736800_dkaf435-B11","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1128\/AAC.02526-12","article-title":"Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus","volume":"57","author":"Gilmer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01885-19","article-title":"Exebacase demonstrates in vitro synergy with a broad range of antibiotics against both methicillin-resistant and methicillin-susceptible Staphylococcus aureus","volume":"64","author":"Watson","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00482-20","article-title":"Effect of the lysin exebacase on cardiac vegetation progression in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis as determined by echocardiography","volume":"64","author":"Shah","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-023-06468-y","article-title":"In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires","volume":"16","author":"Karau","year":"2023","journal-title":"BMC Res Notes"},{"key":"2026011413271736800_dkaf435-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01078-19","article-title":"Antimicrobial activity of exebacase (lysin CF-301) against the most common causes of infective endocarditis","volume":"2","author":"Watson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B16","doi-asserted-by":"publisher","first-page":"550853","DOI":"10.3389\/fmed.2021.550853","article-title":"Arthroscopic \u201cdebridement and implant retention\u201d with local administration of exebacase (lysin CF-301) followed by suppressive tedizolid as salvage therapy in elderly patients for relapsing multidrug-resistant S. epidermidis prosthetic knee infection","volume":"8","author":"Ferry","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026011413271736800_dkaf435-B17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/aac.00588-22","article-title":"Activity of exebacase (CF-301) against biofilms formed by Staphylococcus epidermidis strains isolated from prosthetic joint infections","volume":"66","author":"Souche","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B18","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-Seventh Edition: M100","author":"CLSI","year":"2017"},{"key":"2026011413271736800_dkaf435-B19","doi-asserted-by":"publisher","first-page":"e0258720","DOI":"10.1128\/AAC.02587-20","article-title":"Development of a broth microdilution method for exebacase susceptibility testing","volume":"65","author":"Oh","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.mib.2008.09.012","article-title":"Bacteriophage lysins as effective antibacterials","volume":"11","author":"Fischetti","year":"2008","journal-title":"Curr Opin Microbiol"},{"key":"2026011413271736800_dkaf435-B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40268-022-00383-6","article-title":"Exebacase: a novel approach to the treatment of staphylococcal infections","volume":"22","author":"McCarthy","year":"2022","journal-title":"Drugs R D"},{"key":"2026011413271736800_dkaf435-B22","doi-asserted-by":"crossref","first-page":"114879","DOI":"10.1016\/j.diagmicrobio.2019.114879","article-title":"In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015\u20132017.","volume":"95","author":"Traczewski","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026011413271736800_dkaf435-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02666-16","article-title":"Bacteriophage lysin CF-301, a potent antistaphylococcal biofilm agent","volume":"61","author":"Schuch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B24","doi-asserted-by":"publisher","first-page":"115471","DOI":"10.1016\/j.diagmicrobio.2021.115471","article-title":"Anti-staphylococcal lysin, LSVT-1701, activity: in vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019","volume":"101","author":"Huang","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026011413271736800_dkaf435-B25","doi-asserted-by":"publisher","first-page":"e02176-19","DOI":"10.1128\/AAC.02176-19","article-title":"Synergistic activity of exebacase (CF-301) in addition to daptomycin against Staphylococcus aureus in a neutropenic murine thigh infection model","volume":"64","author":"Asempa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B26","doi-asserted-by":"publisher","first-page":"e0050821","DOI":"10.1128\/AAC.00508-21","article-title":"Efficacy of antistaphylococcal lysin LSVT-1701 in combination with daptomycin in experimental left-sided infective endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"65","author":"Huang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413271736800_dkaf435-B27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5194\/jbji-7-169-2022","article-title":"Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis","volume":"7","author":"Karau","year":"2022","journal-title":"J Bone Jt Infect"},{"key":"2026011413271736800_dkaf435-B28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/cid\/ciab1015","article-title":"Safety and pharmacokinetics of exebacase in an infant with disseminated Staphylococcus aureus infection","volume":"75","author":"Moorthy","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026011413271736800_dkaf435-B29","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1172\/JCI136577","article-title":"Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis","volume":"130","author":"Fowler","year":"2020","journal-title":"J Clin Invest"},{"key":"2026011413271736800_dkaf435-B30","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/cid\/ciae043","article-title":"Exebacase in addition to standard-of-care antibiotics for Staphylococcus aureus bloodstream infections and right-sided infective endocarditis: a phase 3, superiority-design, placebo-controlled, randomized clinical trial (DISRUPT)","volume":"78","author":"Fowler","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026011413271736800_dkaf435-B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.01842-21","article-title":"A phase 1 study to evaluate safety and pharmacokinetics following administration of single and multiple doses of the antistaphylococcal lysin LSVT-1701 in healthy adult subjects","volume":"66","author":"Wire","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf435\/65736095\/dkaf435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf435\/65736095\/dkaf435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:23Z","timestamp":1768415243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf435\/8364735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf435","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,4]]},"article-number":"dkaf435"}}